General

Cell Line

hPSCreg name CSSi014-A
Cite as:
CSSi014-A (RRID:CVCL_B7SH)
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
CTGUi001-A
(FD01, F01)
Donor diseases:
Fabry Disease
UKWNLi007-A
(GLA-515G>A-1, GLA-C172Y-iPSC-1, FD1210/1)
Donor diseases:
Fabry Disease
MDCi007-A
(8993-A12)
Donor diseases:
Leigh Disease
BIHi276-A
Donor's gene variants:
MT-ATP6
Donor diseases:
Leigh Disease
MDCi008-A
(8993-B12)
Donor diseases:
Leigh Disease
MDCi010-A
(8993-D7)
Donor diseases:
Leigh Disease
BIHi267-B
Donor's gene variants:
MT-ATP6
Donor diseases:
Leigh Disease
BGUi001-A
(BGU01iPORhet)
Donor diseases:
P450 Oxidoreductase Deficiency
BGUi002-A
(BGU02iPOR)
Donor diseases:
P450 Oxidoreductase Deficiency
BGUi003-A
(BGU03iPOR)
Donor diseases:
P450 Oxidoreductase Deficiency
UNIZARi001-A
(FiPSTK2-2)
Donor's gene variants:
TK2, TK2
Donor diseases:
Mitochondrial DNA depletion syndrome, myopathic form
TIGETi003-A
(GLD1.3)
Donor diseases:
Krabbe disease
Last update 27th June 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Fondazione Casa Sollievo della Sofferenza IRCCS (CSS)
Owner Fondazione Casa Sollievo della Sofferenza IRCCS (CSS)
Distributors
Derivation country Italy

External Databases

BioSamples SAMEA14252991
Cellosaurus CVCL_B7SH
Wikidata Q112929420

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Ethnicity caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
Karyotyping method: G-Banding

External Databases (Donor)

BioSamples SAMEA14258819

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? No
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? No
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? REGIONE DEL VENETO-AZIENDA OSPEDALIERA DI PADOVA COMITATO ETICO PER LA SPERIMENTAZIONE CLINICA DELLA PROVINCIA DI PADOVA
Approval number Prot. n. 0040352
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
Yes
Methods used
RT-PCR

Vector free reprogramming

Other

Selection criteria for clones marker expression, morphology
Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Mechanically
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: Nutristem XF
Main protein source:
Serum concentration: %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
Morphology pictures
Clone.tif
iPSC morphology
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
FOXA2
Yes
SOX17
Yes
GATA4
Yes
Morphology
Endoderma.tif
Primitive endodermal structure
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
EOMES
Yes
TBXT
Yes
Morphology
Mesoderma.tif
immature cartilagine
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
PAX6
Yes
NESTIN
Yes
SOX1
Yes
Morphology

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Karyotype
Karyotyping method: G-Banding

Other Genotyping (Cell Line)